Abstract
In a double-blind controlled study lasting 8 weeks, 50 anxious psychoneurotic outpatients with a primary diagnosis of generalized anxiety or panic disorder were randomly assigned to alprazolam (n=30), a new benzodiazepine, or placebo (n=20), after a washout period of 1 week. Alprazolam at dosages between 0.25 and 3 mg/day was found to be significantly better than placebo in the treatment of either disorder. The finding that alprazolam was effective in the treatment of panic disorder is of interest as this diagnostic category is usually treated with tricyclic antidepressants or MAO inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aden GC, Thein SG Jr (1980) Alprazolam compared to diazepam and placebo in the treatment of anxiety. J Clin Psychiatry 41:245–248
Cohn JB (1981) Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J Clin Psychiatry 42:347–351
Davis JM, Nasr S, Spira N, Vogel C (1981) Anxiety: Differential diagnosis and treatment from a biologic perspective. J Clin Psychiatry 42:4–14
Fabre LF, Harris RT (1974) Pilot open-label study on U-31, 889 in anxious inpatients. Curr Ther Res 16:1010–1013
Fabre LF, McLendon DM (1979) A double-blind study comparing the efficacy and safety of alprazolam with diazepam and placebo in anxious outpatients. Curr Ther Res 25:519–526
Greiss KC, Fogari R (1980) Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety. J Clin Pharmacol 20:693–699
Guy W (ed) (1976) ECDEU Assessment Manual for Psychopharmacology (revised), Rockville, MD, National Institute of Mental Health Psychopharmacology Research Branch
Itil TM, Polvan N, Egilmez S, Saletu B, Marasa J (1973) Anxiolytic effects of a new triazolobenzodiazepine, U-31, 889. Curr Ther Res 15:603–615
Itil TM, Saletu B, Marasa J, Mucciardi AN (1972) Digital computer analysed awake and sleep EEG (sleep prints) in predicting the effects of a triazolobenzodiazepine (U-31, 889). Pharmokopsychiat Neuropsychopharmakol 5:225–240
Kolin I, Linet OI (1981) Double-blind comparison of alprazolam and diazepam for subchronic withdrawal alcohol. J Clin Psychiatry 42:169–173
McLendon DM, Fabre LF (1979) A double-blind comparison of the anxiolytic efficacy of alprazolam and chlordiazepoxide hydrochloride in the chronic withdrawal period from alcohol. Curr Ther Res 26:430–439
McLendon DM, Fabre LF (1980) A double-blind comparison of the efficacy of alprazolam, chloridazepoxide hydrochloride and placebo in the chronic withdrawal period from alcohol. Curr Ther Res 28:447–455
Moschitto LJ, Greenblatt DJ, Divoll M, Abernethy DR, Smith RB, Shader RI (1981) Alprazolam kinetics in the elderly: Relation to antipyrine disposition. Clin Pharmacol Ther 29:267
Rickels K, Downing RW, Winokur A (1978) Antianxiety drugs: Clinical use in psychiatry. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of Psychopharmacology, Vol 13. Plenum, New York, pp 395–430
Rudzik AD, Hester JB, Tang AH, Straw RN, Friis W (1973) Triazolobenzodiazepines, a new class of central nervous system-depressant compounds. In: Garattini S, Mussini E, Randall LO (eds) The benzodiazepines. Raven, New York, pp 285–297
Schatzberg AF, Cole JO (1981) Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders. Br J Clin Pharmacol 11:175–225
Spitzer RL, Endicott J, Robins E (1977) Research Diagnostic Criteria, 3rd Edition, Biometrics Research, New York State Psychiatric Institute, New York
Zitrin CM, Klein DF, Woerner MG (1978) Behavior therapy, supportive psychotherapy, imipramine and phobias. Arch Gen Psychiatry 35:307–316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chouinard, G., Annable, L., Fontaine, R. et al. Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 77, 229–233 (1982). https://doi.org/10.1007/BF00464571
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00464571